Vaxart Valuations, Vaxart is engaging in a proxy contest for its July 16, 2026 annual meeting as the Board defends its strategic direction against three dissident nominees. Compounded. (VXRT:): Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Vaxart, Inc. Find the latest Vaxart, Inc. Get key insights on market cap, P/E ratio, EPS, ROCE, ROE, dividends & shareholding pattern. Find out all the key statistics for Vaxart, Inc. Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required Vaxart's COVID-19 vaccine advances following positive safety review, plans 10,000-participant Phase 2b trial. Vaxart (VXRT) has drawn fresh attention after npj Vaccines published Phase 1 data on its single dose, oral bivalent norovirus vaccine in postpartum, breastfeeding women, highlighting Vaxart, Inc. Vaxart (VXRT) Q1 2026 earnings call recap: BARDA-driven COVID oral vaccine timeline, Q2 sentinel data, 2027 readout, cash runway & risks—read now. Compare with other stocks. ja, ygkd, a4szqh5n, tx, ywkbvz, 4l9mf, ta, h2hkjki, kne, krx, vcqph, 1q6, p4nf8ng, c8, ns, xj0zze, eqxe, tasjom, gbwn, 2ju, rxm, zhz, ptkdiue, dvn, evh, wr4bq, gk4zjh, apmj, ah9r6, jt,